(Reuters) – U.S. drugmaker Merck & Co Inc has initiated a rolling submission to Health Canada for Molnupiravir, an oral antiviral therapy treatment for COVID-19, it said in a statement on Friday.
Molnupiravir is being developed by Merck and Ridgeback Biotherapeutics for the treatment of non-hospitalized COVID-19 patients.
(Reporting by Juby Babu in Bengaluru; Editing by Leslie Adler)
